Literature DB >> 6183397

Interferon production in mouse spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus.

Y Ito, Y Nagai, K Maeno.   

Abstract

Interferon production in mouse spleen cells and mouse fibroblasts (L cells) stimulated by three strains of Newcastle disease virus (NDV), Italian, La Sota and Ulster, was investigated. Strain Italian was fully infectious and highly virulent; strain Ulster exhibited very low infectivity and very low virulence; strain La Sota was between these extremes. All of these strains of MDBK cell-grown NDV could induce interferon in mouse spleen cells, and it was concluded that proteolytic cleavage of F0 protein of NDV and, consequently, virus penetration are not necessary for interferon induction in these cells. On the other hand, NDV with uncleaved F0, which was characterized by an apparent lack of haemolytic and cell fusion activity and infectivity for tissue culture cells, had no interferon-inducing ability in L cells. The cleavage of F0 protein was paralleled by an appearance of interferon-inducing activity in L cells.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6183397     DOI: 10.1099/0022-1317-62-2-349

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

1.  Green fluorescent protein reporter system with transcriptional sequence heterogeneity for monitoring the interferon response.

Authors:  Linah Mahmoud; Maher Al-Saif; Haitham M Amer; Mustafa Sheikh; Fahad N Almajhdi; Khalid S A Khabar
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

2.  Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Authors:  Subbiah Elankumaran; Vrushali Chavan; Dan Qiao; Raghunath Shobana; Gopakumar Moorkanat; Moanaro Biswas; Siba K Samal
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

3.  Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines.

Authors:  Sateesh Krishnamurthy; Toru Takimoto; Ruth Ann Scroggs; Allen Portner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity.

Authors:  V Schirrmacher; R Heicappell
Journal:  Clin Exp Metastasis       Date:  1987 Apr-Jun       Impact factor: 5.150

5.  Effects of a heat-labile factor(s) in normal serum on the interferon-inducing activity of Newcastle disease virus (NDV). Brief report.

Authors:  F Taguchi; Y Nishimura
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

6.  Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.

Authors:  Xing Cheng; Weijia Wang; Qi Xu; James Harper; Danielle Carroll; Mark S Galinski; JoAnn Suzich; Hong Jin
Journal:  J Virol       Date:  2016-05-12       Impact factor: 5.103

Review 7.  Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer.

Authors:  Volker Schirrmacher; Philippe Fournier
Journal:  Methods Mol Biol       Date:  2009

8.  Generation of mouse small intestinal epithelial cell lines that allow the analysis of specific innate immune functions.

Authors:  Johannes Schwerk; Mario Köster; Hansjörg Hauser; Manfred Rohde; Marcus Fulde; Mathias W Hornef; Tobias May
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

Review 9.  Induction of interferon by virus glycoprotein(s) in lymphoid cells through interaction with the cellular receptors via lectin-like action: an alternative interferon induction mechanism.

Authors:  Y Ito
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

10.  More than one component of the Newcastle disease virus particle is capable of interferon induction.

Authors:  K Wertz; M Büttner; A Mayr; O R Kaaden
Journal:  Vet Microbiol       Date:  1994-04       Impact factor: 3.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.